Sign in

Libo Bio · 砺博生物

Series A · nearly CNY 100M · October 2026 · Biotech & pharma · China

What it sells

Targeted RNA small-molecule drug development

Funding history and coverage

Round dateStageAmountInvestorsSource
2026-10-31Series Anearly CNY 100M正心谷资本 (lead), 创新工场news.google.com
2026-10-30Series Anearly CNY 100M正心谷资本 (lead)news.google.com
2026-10-30Series Anearly CNY 100M—news.google.com
2026-10-30Series Anearly CNY 100M—news.google.com

Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-11-01.

More startups in Biotech & pharma

  1. Formation

    Formation Bio is a tech-driven, AI-native pharma company that acquires and develops clinical-stage assets, and has launched a $600M Drug Development Accelerator Fund.

    $600M · 2026-10-30Biotech & pharmaNorth America

  2. ALLOX

    ALLOX uses genetics and AI in high-throughput experiments to learn the biophysical parameters governing protein function, mapping functional hotspots to accelerate the discovery…

    Seed · $10.5M · 2026-10-29Biotech & pharmaEurope

  3. StimCardio

    StimCardio Medical is developing a non-invasive wearable neuromodulation platform combining continuous physiological sensing with personalized therapy, starting with atrial…

    Series A · $30M · 2026-10-29Biotech & pharmaOther regions

  4. Coherence Neuro

    Coherence designs therapeutic neurotechnology to manage cancer from inside the body; its flagship SOMA is a brain-computer interface with a wireless coin-sized implant, an…

    Series A · $45M · 2026-10-28Biotech & pharmaNorth America

  5. Samplix

    Single-cell analysis and isolation technology (Xdrop instrument, consumables and digital tools) with applications in immunotherapy, antibody discovery, screening and genomics.

    €25M · 2026-10-28Biotech & pharmaEurope

  6. Atlas Bio

    Atlas Bio runs in silico clinical trials in immunology using a foundation AI model of human biology to predict and compare patient responses across treatments and indications.

    $12.5M · 2026-10-27Biotech & pharmaEurope

All startups in this market →